Topic: non-small cell lung cancer
When 2018 began, there was still plenty of uncertainty for I-O drugmakers in lung cancer. But as 2019 nears, Merck's dominance looks pretty clear.
AstraZeneca felt the blow last month when key trial Mystic failed. But now that the dust has settled, it's looking for bright spots in the miss.
Merck’s Keytruda finally has some immuno-oncology competition in first-line, non-small cell lung cancer, courtesy of Roche.
Hutchison China MediTech’s Elunate, which was the first China-made drug to win a major oncology approval, has flopped in a key lung cancer trial.
AZ put skeptics to rest with a long-promised "return to growth." But it’s still far from its $40B sales goal—and its CEO doubled down on it anyway.
In June, Merck upstaged Roche with squamous non-small cell lung cancer data. And thanks to a new nod, it looks like it’ll beat Roche to market, too.
Seventeen cancer drugs from global and local drugmakers take an average 56.7% discount to win spots on China's insurance scheme.
It’s been a long road for Pfizer’s dacomitinib, but the targeted lung cancer drug finally has an FDA green light.
U.S. medtech exports to China are targets in trade war; Alunbrig beats Xalkori in 1st-line lung cancer; FDA blasts Huahai for careless process changes.
AstraZeneca already has an Imfinzi OK in lung cancer maintenance. But new survival data will strengthen its case—and its lead over its I-O rivals.